23andMe Co-Founder and CEO Anne Wojcicki speaks onstage throughout TechCrunch Disrupt SF 2017 at Pier 48 on September 19, 2017 in San Francisco, California.
Shares of 23andMe sank 21% on Thursday, a day after the genetic testing company reported dismal fiscal third-quarter outcomes and mentioned splitting itself in two to assist juice its stock price.
23andMe reported income of $45 million for the quarter, down from the $67 million it reported in the identical interval final 12 months. The company mentioned its web loss for the quarter was $278 million, which is steeper than the online lack of $92 million it reported within the year-ago quarter.
The stock was buying and selling at round 56 cents on Thursday.
In November, 23andMe obtained a deficiency letter from the Nasdaq Listing Qualifications Department giving the company 180 days to convey its share price again above $1, in accordance to a filing with the U.S. Securities and Exchange Commission. If 23andMe fails to comply, it will likely be delisted from the alternate.
During 23andMe’s quarterly name with traders, co-founder and CEO Anne Wojcicki mentioned the company is contemplating splitting up its shopper and therapeutics companies to assist increase its investor base.
“We haven’t made any definitive selections about what we’re going to do, however there [are] undoubtedly alternatives and issues that we’re exploring with probably having therapeutics be unbiased versus shopper,” she mentioned.
Founded in 2006, 23andMe exploded in recognition due to its at-home DNA testing kits that give shoppers insights into their ancestry and genetic profiles. The five-time CNBC Disruptor 50 company went public in 2021 through a merger with a particular objective acquisition company, a deal that valued the company at round $3.5 billion.
Wojcicki, the previous partner of Google founder Sergey Brin, briefly reached billionaire standing after the IPO, touchdown spots on Forbes’ “Power Women” and “America’s Self-Made Women” lists.
But 23andMe has struggled to generate regular recurring income since shoppers solely wanted to take its DNA check as soon as so as to obtain their outcomes. The company has launched extra therapeutics and analysis companies, however its share price has tumbled greater than 95% from its peak.
For its full fiscal 12 months in 2024, 23andMe mentioned it expects to report income between $215 million and $220 million, down from the $240 million to $250 million vary the company guided last quarter.
23andMe can also be going through mounting authorized troubles because it faces greater than 30 class action lawsuits following a knowledge breach it disclosed late last year. Hackers accessed delicate info like names, ancestry stories, beginning years and extra from up to 6.9 million people, a spokesperson confirmed to TechCrunch.
CFO Joe Selsavage mentioned the company has incurred $2.7 million in bills to date associated to the information breach.
“We now require two-factor authentication from all of our prospects, and we realized that our enterprise actually runs on the belief of our prospects,” Selsavage mentioned in the course of the earnings name.
Analysts at Citi mentioned the continued class motion claims, in addition to “persistent headline/reputational danger,” has made them cautious about 23andMe’s outlook, in accordance to a notice Thursday. They lowered their goal price for the stock to 85 cents from 90 cents.
Don’t miss these tales from CNBC PRO: